Ocular complications with MEK inhibitor treatment often involve retinopathy that manifests within hours to weeks of treatment initiation, with recovery upon drug interruption, dose reduction or discontinuation in most cases [22, 23]. The gene discussed is MAP2K7; the disease is retinal disorder.